Skip to content

RNA

Avidity Biosciences, Inc.

NASDAQ · Healthcare · Biotechnology · US

$8.95
−6.38%
Ask drillr

Year over year

Reported trailing growth

Revenue
+119.0%
EBITDA
+81.7%
EBIT
+81.5%
EPS
-8.1%
Free cash flow
+91.5%
Operating cash flow
+91.6%

Forward estimates

Based on analyst estimates

Revenue
-6.3%
EBITDA
-3.7%
EPS
-51.9%

Three-year CAGR

Revenue
+26.4%
EBITDA
+79.7%
EBIT
+79.7%
Net income
+76.2%
EPS
-55.0%
Free cash flow
+86.2%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026